Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anorexia Nervosa01:28

Anorexia Nervosa

Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Bulimia Nervosa01:30

Bulimia Nervosa

Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cinnamaldehyde, a major bioactive component of cinnamon bark, enhances social approach behavior associated with a liver-brain FGF21-isotocin axis in zebrafish.

Food & function·2026
Same author

Methods to build and maintain effective clinician-patient relationships for adults with disorders of gut-brain interaction (DGBI): a systematic review.

Journal of gastroenterology·2026
Same author

Ninjin'yoeito Kampo medicine enhances zebrafish endurance under forced-swimming conditions via muscle hypertrophy.

Journal of natural medicines·2026
Same author

Resolution of Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome symptoms following kanshoho, a low-pressure muscle relaxation technique: A case report.

Explore (New York, N.Y.)·2026
Same author

Therapeutic Potential of the Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet in Functional Dyspepsia: A Systematic Review.

Digestion·2026
Same author

Development of a Specific Competitive ELISA for Plasma Adropin Levels and Its Application to Investigating Energy Homeostasis in Mice.

Biological & pharmaceutical bulletin·2025

Related Experiment Video

Updated: May 10, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Plasma klotho levels decrease in both anorexia nervosa and obesity.

Marie Amitani1, Akihiro Asakawa, Haruka Amitani

  • 1Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Nutrition (Burbank, Los Angeles County, Calif.)
|June 25, 2013
PubMed
Summary
This summary is machine-generated.

Klotho levels are lower in individuals with obesity and anorexia nervosa (AN). Klotho may indicate a normal nutritional status, with levels rising after BMI recovery in AN patients.

Keywords:
AdiponectinAgingBody mass indexKlothoObesityRestricting-type anorexia nervosa

More Related Videos

Assessing Activity-based Anorexia in Mice
08:26

Assessing Activity-based Anorexia in Mice

Published on: May 14, 2018

Related Experiment Videos

Last Updated: May 10, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Assessing Activity-based Anorexia in Mice
08:26

Assessing Activity-based Anorexia in Mice

Published on: May 14, 2018

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Nutritional Science

Background:

  • Klotho, a hormone, plays a role in aging and metabolic regulation.
  • Altered klotho levels are implicated in various metabolic conditions, including obesity and eating disorders.

Purpose of the Study:

  • To investigate the relationship between plasma klotho levels and body mass index (BMI) in patients with restricting-type anorexia nervosa (r-AN) and obesity.
  • To compare klotho levels in obese patients, r-AN patients, and healthy controls.

Main Methods:

  • Measured plasma klotho, adiponectin, and adiponectin isoform levels.
  • Compared these levels across three groups: 11 obese patients, 12 r-AN patients, and 11 control participants.

Main Results:

  • Plasma klotho levels were significantly lower in both the obesity and r-AN groups compared to controls.
  • In r-AN patients, plasma klotho levels increased significantly following BMI recovery.
  • Adiponectin levels decreased in obesity but showed no correlation with klotho levels.

Conclusions:

  • Lower klotho levels in r-AN and obesity may be linked to the progression of these disorders.
  • Klotho may serve as a biomarker for nutritional status.
  • Further research is needed to elucidate the precise role of klotho in metabolic health and eating disorders.